Current regimens for induction therapy of pediatric acute lymphoblastic leukemia (ALL), or for re-induction post relapse, use a combination of vincristine (VCR), a glucocorticoid, and l-asparaginase (ASP) with or without an anthracycline. With cure rates now approximately 80%, robust pre-clinical models are necessary to prioritize active new drugs for clinical trials in relapsed/refractory patients, and the ability of these models to predict synergy/antagonism with established therapy is an essential attribute. In this study, we report optimization of an induction-type regimen by combining VCR, dexamethasone (DEX) and ASP (VXL) against ALL xenograft models established from patient biopsies in immune-deficient mice. We demonstrate that the VXL combination was synergistic in vitro against leukemia cell lines as well as in vivo against ALL xenografts. In vivo, VXL treatment caused delays in progression of individual xenografts ranging from 22 to >146 days. The median progression delay of xenografts derived from long-term surviving patients was 2-fold greater than that of xenografts derived from patients who died of their disease. Pharmacokinetic analysis revealed that systemic DEX exposure in mice increased 2-fold when administered in combination with VCR and ASP, consistent with clinical findings, which may contribute to the observed synergy between the 3 drugs. Finally, as proof-of-principle we tested the in vivo efficacy of combining VXL with either the Bcl-2/Bcl-xL/Bcl-w inhibitor, ABT-737, or arsenic trioxide to provide evidence of a robust in vivo platform to prioritize new drugs for clinical trials in children with relapsed/refractory ALL.
References
[1]
Pui CH, Pui C-H (2010) Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc 109: 777–787.
Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, et al. (2010) Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol 28: 648–654.
[4]
Chessells JM, Veys P, Kempski H, Henley P, Leiper A, et al. (2003) Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 123: 396–405.
[5]
Arico M, Schrappe M, Hunger SP, Carroll WL, Conter V, et al. (2010) Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 28: 4755–4761.
[6]
Pui CH, Carroll WL, Meshinchi S, Arceci RJ, Pui C-H, et al. (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 29: 551–565.
[7]
Schwartz CL (1999) Long-term survivors of childhood cancer: the late effects of therapy. Oncologist 4: 45–54.
[8]
Skinner R, Wallace WH, Levitt GA (2006) Long-term follow-up of people who have survived cancer during childhood. Lancet Oncol 7: 489–498.
[9]
Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, et al. (2010) Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference. Pediatr Blood Cancer 54: 872–878.
[10]
Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711–715.
[11]
Peterson JK, Houghton PJ (2004) Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40: 837–844.
[12]
Inaba M, Kobayashi T, Tashiro T, Sakurai Y (1988) Pharmacokinetic approach to rational therapeutic doses for human tumor-bearing nude mice. Jpn J Cancer Res 79: 509–516.
[13]
Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, et al. (1998) Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90: 505–511.
[14]
Baersch G, Mollers T, Hotte A, Dockhorn-Dworniczak B, Rube C, et al. (1997) Good engraftment of B-cell precursor ALL in NOD-SCID mice. Klin Padiatr 209: 178–185.
[15]
Borgmann A, Baldy C, von Stackelberg A, Beyermann B, Fichtner I, et al. (2000) Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol 17: 635–650.
[16]
Steele JP, Clutterbuck RD, Powles RL, Mitchell PL, Horton C, et al. (1997) Growth of human T-cell lineage acute leukemia in severe combined immunodeficiency (SCID) mice and non-obese diabetic SCID mice. Blood 90: 2015–2019.
[17]
Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, et al. (2004) Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103: 3905–3914.
[18]
Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, et al. (2002) The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 99: 4100–4108.
[19]
Nijmeijer BA, Mollevanger P, van Zelderen-Bhola SL, Kluin-Nelemans HC, Willemze R, et al. (2001) Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. Exp Hematol 29: 322–329.
[20]
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677–681.
[21]
Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A (2008) BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111: 2300–2309.
[22]
Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, et al. (2007) BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12: 171–185.
[23]
Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, et al. (2007) Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110: 2057–2066.
[24]
High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, et al. (2010) The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 77: 483–494.
[25]
Bornhauser BC, Bonapace L, Lindholm D, Martinez R, Cario G, et al. (2007) Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood 110: 2084–2091.
[26]
Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, et al. (2007) Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 67: 32–40.
[27]
Ek O, Gaynon P, Zeren T, Chelstrom LM, Myers DE, et al. (1998) Treatment of Human B-Cell Precursor Leukemia in SCID Mice by Using a Combination of the Anti-CD19 Immunotoxin B43-PAP with the Standard Chemotherapeutic Drugs Vincristine, Methylprednisolone, and L-Asparaginase. Leukemia & Lymphoma 31: 143–149.
[28]
Yang J, Wu H, Zhang P, Hou DM, Chen J, et al. (2008) The pharmacokinetic profiles of dexamethasone and methylprednisolone concentration in perilymph and plasma following systemic and local administration. Acta Oto-Laryngol 128: 496–504.
[29]
Yang L, Panetta JC, Cai X, Yang W, Pei D, et al. (2008) Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 26: 1932–1939.
[30]
Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253–265.
[31]
Dumontet C, Sikic BI (1999) Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061–1070.
[32]
Bachmann PS, Gorman R, Papa RA, Bardell JE, Ford J, et al. (2007) Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res 67: 4482–4490.
[33]
Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, et al. (2010) Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 116: 3013–3022.
[34]
Narta UK, Kanwar SS, Azmi W (2006) Pharmacological and clinical evaluation of l-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol.
[35]
Su N, Pan YX, Zhou M, Harvey RC, Hunger SP, et al. (2008) Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer 50: 274–279.
[36]
Lonnerholm G, Frost BM, Abrahamsson J, Behrendtz M, Castor A, et al. (2008) Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. Br J Haematol 142: 616–621.
[37]
Frost BM, L？nnerholm G, Koopmans P, Abrahamsson J, Behrendtz M, et al. (2003) Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta P？diatrica 92: 551–557.
[38]
Puisset F, Dalenc F, Chatelut E, Cresteil T, Lochon I, et al. (2005) Dexamethasone as a probe for vinorelbine clearance. Br J Clin Pharmacol 60: 45–53.
[39]
Toth GG, Pas HH, Jonkman MF, Toth GG, Pas HH, et al. (2002) Transition of pemphigus vulgaris into pemphigus foliaceus confirmed by antidesmoglein ELISA profile. Int J Dermatol 41: 525–527.
[40]
Avramis VI, Panosyan EH, Avramis VI, Panosyan EH (2005) Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 44: 367–393.
[41]
Albertsen BK, Schroder H, Jakobsen P, Muller HJ, Carlsen NT, et al. (2001) Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol 52: 433–437.
[42]
Pieters R, Appel I, Kuehnel HJ, Tetzlaff-Fohr I, Pichlmeier U, et al. (2008) Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood 112: 4832–4838.
[43]
Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, et al. (2007) Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 67: 1176–1183.
[44]
Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, et al. (2008) Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatric Blood Cancer 50: 1181–1189.
[45]
Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, et al. (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375–388.
[46]
Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, et al. (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 103: 14907–14912.
[47]
Kang MH, Reynolds CP, Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15: 1126–1132.
[48]
Vogler M, Dinsdale D, Dyer MJ, Cohen GM, Dyer MJS (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16: 360–367.
[49]
Litzow MR, Lee S, Bennett JM, Dewald GW, Gallagher RE, et al. (2006) A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica 91: 1105–1108.
[50]
Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds CP (2005) DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 110: 139–153.
[51]
Kaplan PMEL (1958) Nonparametric Estimation from Incomplete Observation. J Am Stat Assoc 53: 457–481.
[52]
Rose WC, Wild R (2004) Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts. Clin Cancer Res 10: 7413–7417.
[53]
Beal SL (2006) NONMEM Users' Guide. Introduction to version IV. Ellicott City, MD: ICON Development Solutions.
